Compound Libraries

Activity: Comprises 81 highly selective inhibitors of various kinases . Function/Pharmacology: The IntelliScreen™ Highly Selective Kinase Inhibitor Library represents a targeted collection of compounds chosen for their specificity. Notorious for their lack of specificity, some of the oldest and most familiar inhibitors are among the most indiscriminate, inhibiting an array of kinases from multiple kinase families. While occasionally this promiscuity can be beneficial in biological applications, it tends to be an obstacle in pathway or target identification. This library is designed to offer researchers a compact collection of inhibitors deliberately chosen for their high selectivity for an individual target. This high degree of selectivity increases reliability, reduces ambiguity, and helps to limit the amount of additional testing required after screening.

Activity: Comprises 171 modulators of various aspects of cancer cell metabolism . Function/Pharmacology: Concentrations vary based on effective concentrations… see library compound list.

A unique collection of 2808 approved drugs for high throughput screening (HTS) and high content screening (HCS);

3158 compounds from marketed drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 343 protease and proteasome inhibitors for research in chemical genomics, and drug screening;

A unique collection of 142 microtubule-targeted compounds can be used in HTS and HCS;

80 well-chosen unique AMPK-targeted small molecules；

Well-chosen 1090 compounds related to epigenetic regulation for research in epigenetics, high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 420 compounds targeting PI3K/Akt/mTOR signaling for research in PI3K/Akt/mTOR signaling, and drug discovery in diseases involved with PI3K/Akt/mTOR signaling;